New research reveals that only one in four adolescent residential treatment centers across the country provides a medication used to treat opioid use disorder, despite an ever-rising number of overdose deaths among young people nationwide resulting from a surge of illicit fentanyl.
The study, led by researchers at Oregon Health & Science University, published today in the Journal of the American Medical Association.
Researchers say the lack of buprenorphine in adolescent residential treatment centers undercuts the United States’ efforts to alleviate an overdose epidemic that claimed more than 109,000 lives in 2022, according to predicted provisional statistics from the Centers for Disease Control and Prevention, or CDC. Recognizing the particular vulnerability of young people, especially as fentanyl now contaminates other illicit substances, OHSU researchers set out to determine how many adolescent treatment centers in the U.S. were providing buprenorphine to treat addiction.



.jpg)

.jpg)

.jpg)
.jpg)
